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Abstract
A soluble, short chain phosphatidylserine, 1,2-dicaproyl-sn-glycero-3-phospho-L-serine (C6PS),
binds to discrete sites on FXa, FVa, and prothrombin to alter their conformations, to promote FXa
dimerization (Kd ~ 14 nM), and to enhance both the catalytic activity of FXa and the cofactor
activity of FVa. In the presence of calcium, C6PS binds to two sites on FXa, one in the epidermal
growth factor like (EGF) domain and one in the catalytic domain; the latter interaction is sensitive
to Na+ binding and probably represents a protein recognition site. Here we ask whether
dimerization of FXa and its binding to FVa in the presence of C6PS are competitive processes. We
monitored FXa activity at 5, 20 and 50 nM FXa while titrating with FVa in the presence of 400
µM C6PS and 3 or 5 mM Ca2+ to show that the apparent Kd of FVa-FXa interaction increased
with increasing FXa concentration at 5 mM Ca2+, but the Kd was only slightly affected at 3 mM
Ca2+. A mixture of 50 nM FXa and 50 nM FVa in the presence of 400 µM C6PS yielded both Xa
homodimers and Xa ·Va heterodimers but no FXa dimers bound to FVa. A mutant FXa (R165A)
that has reduced prothrombinase activity showed both reduced dimerization (Kd~147 nM) and
reduced FVa binding (apparent Kd, = 58, 92 and 128 nM, respectively for 5, 20 and 50 nM R165A
FXa). Native gel electrophoresis showed that the GLA-EGFNC fragment of FXa (lacking the
catalytic domain) neither dimerized nor formed a complex with FVa in the presence of 400 µM
C6PS and 5 mM Ca2+. Our results demonstrate that the dimerization site and FVa binding site are
both located in the catalytic domain of FXa and that these sites are linked thermodynamically.
Introduction
Thrombin production, located at the convergence of the three legs of the traditional blood
coagulation cascade, is arguably the central reaction of blood coagulation, and thrombin is
the central metabolite of blood coagulation (1). A complex between two soluble clotting
factors, FXa and FVa, catalyzes the conversion of prothrombin to thrombin. This
prothrombin-activating complex (or prothrombinase) assembles and functions in vivo on
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activated platelet membranes (2, 3). Phosphatidylserine (PS), which, along with
phosphatidylethanolamine, is exposed on activated platelet membranes (4), appears to be the
platelet lipid required for efficient blood coagulation (5). In order to examine the molecular
details of regulation of FXa and FVa by PS, we introduced a soluble (CMC ~ 650–800 µM
depending on exact conditions) form of PS (1,2-dicaproyl-sn-glycero-3-phospho-L-serine,
C6PS) that has allowed us to locate the PS regulatory sites on FXa (6) and FVa (7) and to
establish the regions of these molecules affected by occupancy of these sites by PS. While
C6PS does not occur in vivo, it has proven to be a very important tool in our efforts to reveal
the molecular details of PS regulation of these two coagulation factors and of blood
coagulation in general.
FXa has an N-terminal GLA module essential for membrane binding and two highly Cys-
rich domains (epidermal-growth-factor-like cassettes, EGFN and EGFC) that link the Gla
module to the C-terminal catalytic domain containing the catalytic triad (H/D/S) and FVa
interaction sites (8–11). The EGF cassette pair binds a molecule of C6PS, which is soluble
up to ~700–800 µM under our conditions to form in solution, an inactive dimer (12, 13) or a
60-fold activated monomer (14, 15). Binding of C6PS to the EGF pair is specific for L-
phosphatidylserine (16), triggers binding of a second molecule of C6PS to a Ca2+- and Na+-
dependent site in the catalytic domain and alters the active site (6, 14), and elicits changes in
FXa activity (15) only when the GLA and EGF domains are linked by C6PS binding (6).
FVa is a heterodimer (17) composed of a heavy chain (FVa-HC; A1 & A2 domains; Mr =
105,000 in human) and a light chain (FVa-LC; A3, C1, & C2 domains; Mr = 74,000 or
71,000) (18, 19). Heterogeneity of the light chain is seen in both bovine and human FVa
(18–20) and is due to alternative glycosylation at Asn2181 in the C2 domain (21). The
species that is glycosylated at Asn2181 is termed factor Va1 while the species lacking
glycosylation at this position is factor Va2. FVa2 differs from FVa1 in its ability to bind
tightly to FXa in the presence of phosphatidylserine (PS)-containing membranes or a short-
chain PS (C6PS) (22, 23). For this reason, all of our studies are performed with FVa2 that,
for simplicity, will be referred to as FVa. FVa binds 4 molecules of C6PS, two molecules to
the FVa-HC moiety and two molecules to the FVa-LC moiety (24). PS binding to the C2 site
in FVa-LC is required for tight membrane association (25), while binding to a site in the C1
domain is required for tight association between FXa and FVa on a membrane or in solution
(7). We have not identified a function for the C6PS-binding sites in FVa-HC.
The FVa binding site in FXa is thought to be located in the catalytic domain: residues 162–
169 (8, 9); residues 185–189 (26); and residues 230–245 (27, 28) and is thermodynamically
linked to a Na+ binding site and the active site (29) (numbering is in the chymotrypsin
system). C6PS binding to a regulatory sites in the EGFNC pair (ideally attached to the Gla
(GLA) domain) is also linked to the Na+ binding and active sites (6). C6PS binding to the
regulatory site triggers formation of an inactive FXa dimer in which Lysine 90 in the
catalytic domain becomes buried (13). Because C6PS binding to the regulatory site is linked
to both the FXa dimer- and the Na+/FVa binding regions, we speculated that these binding
regions might be directly linked within the catalytic domain. Here we test this hypothesis
and show that FVa binding and dimerization of FXa are competitive processes. Next, we
show that the GLA-EGFNC fragment of FXa (lacking the catalytic domain) does not
contribute to dimerization or to interaction with FVa, in the presence of C6PS, thus locating
both interactions exclusively to the catalytic domain. Finally, we show that a FXa mutation
in the catalytic domain that interferes with FVa binding (R165A, (8)) also interferes with
both FXa dimer formation, thus locating the linkage between these binding regions to the
catalytic domain. Because these regions are far separated in current molecular models of
FXa, our results imply either that a linkage path exists between them or that PS triggers
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The sodium salt of 1, 2-dicaproyl-sn-glycero-3-phospho-L-serine (C6PS) was purchased
from Avanti Polar Lipids (Birmingham, AL). Human prothrombin and FXa were obtained
from Hematologic Technologies Inc. (Essex Junction, VT). FXa was assayed prior to each
experiment using an active-site titration standard (30) to measure its activity. The R165A
mutant of FXa (chymotrypsin numbering (11)) was expressed and purified as described in
(8) and the GLA-EGFNC fragment of FXa was provided by Dr. Stenflo and prepared as
described in (31). Purified human factor V was prepared from fresh frozen human plasma
(American Red Cross Center, Durham, NC) and then activated to FVa as described (18, 32).
The glycosylated form of human FVa (referred to here as simply FVa) was isolated as
described previously (21, 23). The activity of FVa was assayed using either 25/75 PS/DOPC
vesicles (33)or C6PS (25). Dansylarginine-N- (3-ethyl-1, 5-pentanediyl) amide (DAPA) was
obtained from Haematologic Technologies Inc. (Essex Junction, VT). All other chemicals
were ACS reagent grade; all solvents were HPLC grade.
Short-chain phospholipid sample preparation
Chloroform was removed from measured amounts of C6PS stock using a stream of nitrogen,
and the lipid sample was dissolved in cyclohexane and lyophilized overnight. The
lyophilized lipid was then suspended in an appropriate amount of buffer to reach a desired
concentration and used within 1–2 days.
Critical Micelle Concentration (CMC) Determination
Changes in pyrene florescence were used to document the CMC of C6PS (34). Pyrene
fluorescence has been shown to detect micelles with aggregation numbers as small as 10, as
validated by comparison to CMC determination by surface tension and conductivity
measurements (34, 35).
Native polyacrylamide gel electrophoresis
Separation of protein mixtures and protein standards on native gels of varying percentages
allows the determination of both charge and mass of the sample proteins. The graphic
analysis used is known as the Ferguson Plot (36). The details of the procedures are described
elsewhere (12, 23, 30, 36). Five marker proteins (myosin, BSA, Trypsin inhibitor, α-
lactalbumin, chicken albumin, carbonic anhydrase) were subjected to native polyacrylamide
gel electrophoresis at varying degrees of gel cross-linking, and a Ferguson plot (retardation
coefficient versus molecular weight) was constructed based on their mobilities. FXa, FVa, or
their mixture (50 nM) in 50 mM Tris, 150 mM NaCl, 5 mM CaCl2, pH 7.5, 0.6 % PEG
(buffer A) were incubated at 37°C for 10 minutes in the presence and absence of 400 µM
C6PS. These samples were run together with the marker proteins in 5% or 8%
polyacrylamide gels in a BioRad Mini-Protean II™ minigel apparatus (Biorad Corp.,
Hercules, CA) and stained with colloidal Coomassie blue (37). The molecular masses of Xa,
Va, and their complex were obtained by comparison with the marker proteins.
Prothrombin Activation in the Presence of C6PS
The rate of prothrombin activation was derived from the time-dependent change of DAPA
fluorescence as it bound to the activation products (30). Stopped-flow measurements were
performed at 37°C using an SLM-Aminco Milliflow stopped-flow reactor (Spectronic
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Instruments, Inc., Rochester, NY) attached to the Spex® FluoroLog-3 spectrofluorometer
(Jobin Yvon Inc., Edison, NJ), as described previously (38). Reactions were initiated by
rapidly mixing equal volumes (400 µL) of the contents of the two driving syringes. One
syringe contained prothrombin and DAPA in Buffer A (substrate:DAPA ratio 1:5), and the
other syringe contained pre-assembled prothrombinase (FXa, FVa and C6PS) in the same
buffer. The FVa concentration was varied from 0 to 200 nM.
Results
Dimerization of FXa Affects The Activity of The Prothrombinase Complex at 5 mM Ca+2
The initial rates of thrombin formation by the prothrombinase complex formed at 5, 20 and
50 nM FXa in the presence of 400 µM C6PS and 5 mM Ca2 are plotted in Figure 1B as a
function of FVa concentration. Under these conditions, C6PS is present as a monomer
(CMC be ~650 µM) that binds to FXa to trigger dimer formation (12) and to FVa to trigger
its tight association with FXa in solution (30). Prothrombinase activity decreased with
increasing FXa concentration at a constant FVa concentration, i.e., FXa inhibited
prothrombinase activity. The red hyperbolic curves (single-site binding model for FXa-FVa
interaction) extrapolated to similar saturating activities (kcat/KM ≈ IR/[Xatot]/[S](1000 nM)
= 11 ± 3×107 M−1s−1, 12 ± 1×107 M−1s−1 and 10 ± 1×107 M−1s−1, for 5, 20 and 50 nM
FXa, respectively), meaning that inhibition was overcome at saturating FVa concentration.
The  of FXa-FVa interaction, as estimated from a single-site binding model (solid red
lines in Figure 1B), increased with FXa concentration: 2.2 ±0.6, 20 ±4.2 and 43 ± 13.3 nM
for 5, 20 and 50 nM FXa, respectively. These results suggest that FXa interferes with
prothrombinase complex formation. Because we know that human FXa forms a dimer in
solution in the presence of C6PS (12, 13), it is reasonable to think that this inhibition is due
to formation of inactive FXa dimers, thus, that dimer formation competes with
prothrombinase formation. Using a previously reported Kd for FXa dimerization
 (13), we calculated the potential percent of FXa present as monomer at 5
mM Ca2+ to be 46, 62, and 83 %, at 50, 20, and 5 nM Xatot, respectively (Figure 1B inset),
whereas at 3 mM Ca2+ the potential percent of FXa present as monomer is 94, 97.5, and 99
%, at 50, 20, and 5 nM Xatot, respectively (Figure 2B inset) under the assumption that all
FXa is free to dimerize (i.e., none is tied up in FVa-FXa complex). Because FXa
dimerization is highly sensitive to Ca2+ concentration (12, 13), and 5 mM Ca2+ is the
optimum concentration for FXa dimerization (12, 13), we observed a lower amount of FXa
monomer at 5 mM Ca2+. In the presence of FXa dimers, FVa is required to compete with
FXa to form the prothrombinse complex. The inset to Figure 1B shows that the apparent Kd
of FXa-FVa interaction  decreased as the percent of FXa potentially present as
monomer increased. This result is consistent with FXa dimerization and binding to FVa
being competitive processes. Nonetheless, this result is an insufficient test of competition.
To test the competition hypothesis more quantitatively, we used MatLab to test the ability of
a dimer competition model to account for our observations. Data at all three FXa
concentrations were fit globally as described in detail in Supplement Section A, under
Model 1, and the results are shown in Figure 1B as dashed black curves (▲ 5nM FXa, ■ 20
nM FXa, and ● for 50nM FXa). The kcat/KM that yielded the best fit (9.8 ± 0.9 ×107
M−1s−1; Table 1) was in reasonable agreement with a previous estimate (22 ×107 M−1s−1)
(30). Activity measurements at 37 °C have estimated the Kd of complex formation  as
~3 nM (23), while measurements with active-site labeled human FXa (DEGR-Xa) have
estimated this  as ~ 0.6 nM (7), in good agreement with the value obtained from our fit
of 0.32 (Table 1). Nonetheless, it is evident that the simple competition model significantly
underestimated the degree of observed inhibition of the complex formation at low to
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intermediate FVa concentrations and 50 nM FXa, and thus reached an asymptote well before
the experimental data. Hyperbolic fits to our data (red lines), also suggest this asymptotic
behavior. The reduced chi square (χ̅2) of the fit was large (1.38, Table 1) while its
significance was low (0.1). While the simple dimer competition model confirmed that Xa
dimer formation could result in inhibition of FXa-FVa complex formation, it fell short in its
ability to account quantitatively for our data, leading us to consider alternative models that
might provide better quantitative descriptions of our data.
Because dimer formation underestimated the extent of inhibition, we considered the
possibility that FXa might form a higher order aggregate, e.g., a tetramer (Model 2 in
Section B of Supplement). Model 2 provided no improvement in data description despite
requiring an additional adjustable parameter . As a control, we tried an alternative
form of the “FXa tetramer” model (Model 2a in Section C of Supplement) and found, as
anticipated if our analysis methods were robust, that the results of our fitting were
independent of the thermodynamic path assumed in forming a tetramer. Inability of the
“FXa tetramer” model to fit the data better than the simple dimer competition model (model
1) allows us to reject the “higher-order Xa aggregate” (as embodied to a first approximation
in a tetramer) model to explain inhibition observed at higher concentrations of FXa. Next,
we considered whether aggregation of FVa (Model 3 in Section D of Supplement) and
subsequent formation of an aggregated FXaFVa complex (model 4) might contribute to the
less than satisfactory quantitative description we had obtained using the dimer competition
model (model 1). Both models provided better fit to the data, however the parameter values
were quite unreasonable relative to other reports (  relative to the reported
0.6 nM (7) or to common sense (  means that FVa binds to FVa 100 times more
tightly than it does to FXa). Because we also didn’t see any evidence of FVa dimer in native
gels of mixtures of FVa and FXa in the presence of C6PS (Figure 3), we must conclude that
aggregation of FVa cannot offer an explanation for the poor quantitative agreement between
the FXa dimer competition model (model 1) and our data.
Finally, we considered whether dimerization of the XaVa complex might help account for
our data. The description of our data by this model is better than for any other model
considered (i.e., lowest  for physically reasonable parameters; Table S1). The parameters
for this model ( ; (Kcat / KM)XaVa) were also in reasonable agreement with literature
estimates (30), while the predicted  (150 nM) is consistent with our failure to observe
this species in native gels (Figure 3). However, Figure 1B reveals that the predicted curves
do not approach a common asymptotic (Kcat / KM)XaVa at saturating FVa, which hyperbola
through our data appears to do (see red hyperbolic curves in Figure 1B). Thus, allowing for
a dimer of the FXa-FVa complex considerably improves description of our high FXa data
considerably at low and intermediate FVa concentrations but still falls somewhat short of
accounting for the apparent asymptotic behavior of our data at very high FVa concentration
and 5 mM Ca2+, which favors FXa dimerization.
Dimerization of FXa Affects The Activity of The Prothrombinase Complex at 3 mM Ca+2
We showed previously that FXa dimerization is sensitive to Ca2+ concentration, with  at
3 mM Ca2+ being roughly 40-fold larger than that at 5 mM Ca2+ (12, 13). Thus, to further
test whether FXa dimerization might be a reasonable explanation for the variation with FXa
concentration of  for FXaFVa complex, we repeated the experiments of Figure 1B at 3
mM Ca2+. Surprisingly, Figure 2B still shows inhibition of prothrombinase assembly at
increasing concentrations of FXa, but the inset to Figure 2B shows a 10-fold increase in FXa
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concentration produced a 3–4-fold increase in  at 3 mM Ca2+ (1.7 ±0.2, 5.5 ± 2 and 8
± 2 nM for 5, 20 and 50 nM FXa, respectively) compared to the 20–25-fold increase at 5
mM Ca2+ (Figure 1B inset), suggesting that FXa dimer formation may be less important at 3
mM Ca2+, as expected.
To explore quantitatively the reasons for this unanticipated result, we again used the
procedures described in the Supplement to test the compatibility of our data with the two
most successful models we identified for 5 mM Ca2+ (Model 1: the dimer competition
model and Model 5a: the XaVa dimerization model). Because thermodynamic constants for
XaVa complex formation and human FXa dimer formation are not reported at 3 mM Ca2+,
we measured these constants at 37°C using previously documented methods that use active
site labeled human DEGR-FXa (12, 30) to obtain  and
. This value of  was fixed in our calculations, while  was
adjustable to remain consistent with our computations for 5 mM Ca2. The parameters
providing this fit are summarized in Table 1. The best-fit value for  was somewhat
lower than we measured but still well within the error range of these two estimates. The
effect of Ca2+ on  seen in the context of the dimer competition model is thus small.
Same was also true for (kcat / KM)XaVa (9.8 ±0.8 vs 7.2 ±0.8 ×107 M−1s−1 for 5 and 3 mM
Ca2+, respectively). Apparently, within the context of this model, only FXa dimer formation
was significantly affected by a change in Ca2+ concentration from 5 to 3 mM.
As for 5mM Ca2+, Model 5a (XaVa dimerization) also offered a better description of the
data at 3 mM Ca2+ than did the dimer competition model (model 1). Better description
occurred because the data at 3 mM Ca2+ showed a difference in asymptotic behavior
between 5 and 50 nM FXa, a feature predicted by the XaVa dimerization model. The
parameters defined by this fit are also given in Table 1, where we see that the value for
(kcat / KM)XaVa for the FXa-FVa complex within the context of this model is also not
significantly Ca2+-dependent (11.0 ± 0.9 and 8.7 ± 0.7 ×107 M−1s−1 for 5 and 3 mM Ca2+,
respectively). In addition,  was also not significantly Ca2+-dependent (0.43± 0.2 vs. 0–
2nM for 5 and 3 mM Ca2+, respectively) nor was FXa-FVa complex dimer formation
significantly Ca2+-dependent (150 vs 166 nM for 5 and 3 mM Ca2+, respectively). Thus,
within the context of both models, Ca2+ significantly affected only FXa dimer formation
(  for 5 and 3 mM Ca2+, respectively) in this concentration range.
Coexistence of FXa–FVa Complex with Dimer at 5mM Ca2+
Native polyacrylamide gel electrophoresis, in the presence of C6PS, detects both human
FXa-FVa complex and human FXa dimers of the expected molecular masses (measured
224±3.7 kDa for FXa-FVa (30)) and ~ 90 kDa for (FXa)2 (13). In order for FXa dimer
formation and FXa-FVa complex formation to be competitive processes, the species FVa,
FXa, FXa-FVa, and (FXa)2 should all be able to coexist in equilibrium under a condition for
which both FXa dimers and prothrombinase complex can form (400 µM C6PS, 5 mM Ca2+,
50 nM FXa, and 50 nM FVa). Figure 3A (lane 1) shows FVa (~178KD), FXa2 (~90 KD)
and FXa-FVa complex (~224 KD) bands, thus confirming that FVa monomer FXa dimer
and FXa-FVa complex can all coexist under appropriate conditions. Previous hydrodynamic
studies showed that the solution prothrombinase formed in the presence of C6PS is a 1:1
complex at low FXa concentration (30). These results show that the C6PS-induced complex
is 1:1 even at a FXa concentration for which FXa dimers form. A complex of the FXa dimer
with FVa (FXa·FXa·FVa) should enter the gel (270 KD) and locate to the top of the gel, but
it was not detected. This result is consistent with the hypothesis that only monomer FXa
binds to FVa and that both FXa and FVa compete to bind FXa. Note that the FXa monomer
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does not appear in the gel, because, under these conditions, most FXa is incorporated into
Xa2 or (FXa-FVa). We note also that (FXa-FVa)2 (~ 450 kDa) would not have entered this
5% gel, but we did not detect any staining at the running gel/loading gel interface even at
200 nM FVa.
Thus, if this species is present, it must be present in a small quantity. Not only by simulation
but also directly from experimental data at [FXa]=50 nM, the IR reaches more than 50% of
the final IR at [FVa]=50 nM, which indicates that more than 50% of all species should be in
FXa-FVa form. Is it possible that this occurs due to concentration gradient within the gel?
More massive species travel in the front while less massive species remain in the back, if
FXaVa is disassembling, and it’s reassembly is hindered because FXa is no longer present at
the initial concentration.
A R165A FXa mutation in the FVa Binding Region Interferes with Dimerization
Arg 165 in the human FXa catalytic domain is part of a basic region involved in FVa
binding (8, 9, 26, 27). We also obtained  values for R165A FXa-FVa interaction from
plots of initial rates of prothrombin activation (400 µM C6PS and 5 mM Ca2+) catalyzed by
5, 20 and 50 nM R165A mutant human FXa in the presence of increasing concentrations of
FVa (Table 2). These apparent Kd values along with the  values of the wild type FXa-
FVa (Figure 1B) association are presented in Table2. The results show that the apparent
affinity of the R165A mutant FXa with FVa was lowered by 3–28 fold relative to native
FXa, depending on the concentrations of mutant and wild type FXa. This finding is
consistent with a previous report of a 6-fold effect of this mutation on the interaction with
FXa (39).
The initial rates of prothrombin activation by different concentrations of wild type and
R165A FXa in the presence of 400 µM C6PS versus FXa concentration are plotted in Figure
4. The curves were fit to a dimerization model (12) as described in Methods. The  for
R165A FXa was 9-fold larger than for wild type FXa (Table 2). We conclude that the
R165A mutation alters dimerization as well as binding to FVa in the presence of C6PS.
Role of catalytic domain of FXa in dimerization of FXa and its interaction with FVa
FXa is generally thought to interact with Va through sites in the FXa catalytic domain (8,
10, 27, 40). We wanted to test whether there might be other regions of FXa required for FVa
interaction and dimerization of FXa in the presence of 400 µM C6PS. Figure 3B shows an
8% native polyacrylamide gel of a GLA-EGFNC fragment of FXa (lacking the catalytic
domain) along with intact FXa in the absence and presence of C6PS, showing that FXa
dimerizes but that GLA-EGFNC does not dimerize in the presence of C6PS. Figure 3C
shows a 5% native polyacrylamide gel of FVa in the absence and presence of C6PS and
GLA-EGFNC fragment, showing that FVa cannot form a complex with the GLA-EGFNC
fragment of FXa. Because we have shown previously that native polyacrylamide gel
electrophoresis can detect both FXa dimer and FXa-FVa complexes (12, 30), these results
demonstrate that, although C6PS binds to a regulatory site in the EGFNC pair (6),
interactions between this region of FXa do not contribute directly either to FXa dimerization
or to binding to FVa.
Discussion
Our results support the following conclusions:
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1] FXa dimer formation and prothrombinase complex formation are thermodynamically
competing processes in solution that are both triggered by binding of C6PS to a regulatory
site in the EGFNC pair.
Because of this competition, estimates of the  for prothrombinase complex formation
will depend on the reaction conditions (FXa, FVa, Ca2+ concentrations), at least if activity is
used to monitor prothrombinase formation. This dependence is demonstrated in Figures 1
and 2 but is also surmised from the dimer competition model (Model 1 in Supplement) we
used to interpret our results. Because DEGR-FXa dimerizes weakly in solution (Koklic,
2009 #169}, estimates made of  using active-site-labeled FXa (0.6 ± 0.09 nM (30)) are
lower than estimates made using activity to follow complex assembly (2.8 ± 0.3 nM (23).
Estimates of  using either active-site-labeled FXa or using activity may not differ for
complex assembly on a membrane because DEGR-FXa dimerizes reasonably well on a
membrane surface (41).
2] Other interactions appear to complicate further complex formation in solution.
This conclusion is implied by the observation that the dimer competition model (Model 1 in
Supplement) was unable to account for our data at either 5 mM Ca2+ (where dimerization
should be significant) or 3 mM Ca2+ (where dimer formation should be minimal). In both
instances, less FXa-FVa complex was predicted to form than was suggested by observed
prothrombin-activation rates. We considered what other species might be limiting formation
of prothrombinase complex. Inclusion of higher order aggregates of FXa (tetramer)
produced no reduction in  and produced an estimate of the tetramer dissociation constants
that resulted in this species not being present (Table S1 in Supplement). The possibility that
FVa formed a dimer reduced the  but predicted that the FVa dimer should be the
dominant species, in contradiction with results (Fig. 3A). Next, the assumption that a dimer
of the FXa-FVa complex might form produced an improved description of observations in
Fig. 1 and a significant reduction in  as well as a considerable increase in the goodness of
fit (α, Table 1). FXa-FVa dimer formation (Model 5a in Supplement) also improved our
description of the data collected at 3 mM Ca2+ (Table 1 and Fig. 2) and is concluded to
provide some insight into why the simple dimer competition model does not account well
for our data. Within the context of this model, only the FXa dimerization constant  is
significantly dependent on Ca2+ concentration; neither  nor  were dependent on
Ca2+ concentration, suggesting that formation of (XaVa)2 involves a binding region other
than that involved in Xa2 formation. Since FVa seems not to form a dimer (Model 3 in
Supplement), the most likely interaction region to support formation of the (XaVa)2 species
would be the dimer interaction region. If so, we would have to surmise that binding of FVa
to the FVa binding region of FXa, which is distant from the FXa dimerization region (13),
must alter the dimerization region so that a FXa-FXa interaction becomes more likely at low
Ca2+ concentration. If so, our hypothesis that these two binding regions are linked, is more
credible.
Despite the success of the XaVa dimer model (model 5a) relative to the Xa dimmer
competition model (model 1), the former model at 5 mM Ca2+ still had shortcomings in its
ability to predict observed asymptotic behavior (Fig. 1). Reference to simulations presented
in Figure S3 reveals that the concentration of the prothrombinase complex does not
approach its maximum possible value at high FVa and FXa concentrations because a stable
amount of the FXa-FVa dimer species ((XaVa)2) is predicted to form under these
circumstances. At 3 mM Ca2+, when very little FXa2 species is expected, incomplete
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formation of the prothrombinase complex at high FXa and FVa concentrations is both
predicted (Fig S3) and observed (Fig. 2). This result led us to suspect that the value of 
that we used might be in error. To test this suspicion, we fixed best-fit parameters
( , (Kcat / KM)XaVa) and varied  without producing a better description of
asymptotic behavior. In this regard, we note the large parameter uncertainty for
 (Table 1) that likely reflects the need to rectify different behaviors of the data
at high and intermediate FVa concentrations. The reasons for this discrepancy between the
data and XaVa dimer model (model 5a) at high FVa concentrations could be 1] uneven
distribution of data points, 2] large uncertainties in the rate data at high FVa concentrations
or 3] inadequacy of the model. Indeed, use of an average 12% error for all rate data led to a
somewhat larger 1.3×108 M−1s−1 A (kcat/KM)XaVa, a somewhat improved appearance of the
fit at high FVa and  parameters still within the range of uncertainties shown in
Table 1, but also a somewhat larger . Of course, we must consider that a XaVa dimer may
not explain our observations, but, if not this model, then what model? We know that FXa
forms a dimer in solution under the influence of C6PS (12, 13), and the data in Figures 1 and
2 make it clear that both FXa and FVa concentrations must be taken into account to model
the formation of the active FXa-FVa complex in solution at high FXa and FVa
concentrations. We have eliminated a model that posits a FVa dimer (Model 3 in
Supplement) and models that posit higher order aggregates of FXa (Models 2 and 2a in
Supplement). While we could still imagine other species (e.g., FXa·FXa·FVa), each such
species added to the model adds a new adjustable parameter, meaning that any resulting
improvement in  is less likely to be significant. We conclude that some higher order
aggregated species are required to explain the dependence of soluble prothrombinase
formation on both FXa and FVa concentrations and that the most likely species at this point
is a dimer of the FXa·FVa prothrombinase complex.
3] FVa and FXa binding regions are distinct linked sites within the catalytic domain.
Binding of C6PS to the regulatory site in the EGFNC region (6) of human FXa is linked to
binding sites in the catalytic domain responsible for interaction with FVa and for dimmer
formation (13, 30). Because the EGFN domain is near the membrane-binding Gla domain,
linkage of these sites must occur via the FXa light chain. Because FXa dimer formation and
prothrombinase complex formation are not mediated by C6PS-triggered interactions
between FXa light chains or between FXa light chain and FVa (Fig. 3C), the rules of a
thermodynamic cycle require linkage between the catalytic domain binding regions. Here
we provide additional evidence for this linkage. We know that K90 in the catalytic domain
becomes buried when C6PS triggers FXa dimer formation in the presence of 5 mM Ca2+
and is on the opposite face of a FXa structural model (42) from the most likely FVa binding
regions (either or both of a 185–189 loop (26) or a 162–169 helix containing R165 (8, 9,
27)). Both of these regions were identified by mutational analysis. There are two general
views of linkage (43). One asserts that binding of one ligand favors one of many
conformational states of a protein that favors binding of another ligand. In the second view,
inter-residue or inter-domain interactions along a path convey information between regions
of a protein. Mutational analysis has been proposed to identify such paths (44). Some note
that these views are not mutually exclusive but that “path” residues are residues that are
crucial for protein conformational state equilibration. We show here that a mutation
(R165A) that interferes with FXa interaction with FVa (8) also interferes with dimer
formation (Fig 4). If R165 is in the FVa binding region, this observation supports linkage
between the FVa binding and FXa binding regions. It is noteworthy that another Lys (K230)
becomes exposed upon dimer formation (13) and is spatially close to R165 in the proposed
FXa structural model. These observations suggest that K230 and R165 may be residues that
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are part of a linkage “path” or key to switching between dimer forming or FVa-binding
conformational states, a possibility that also supports linkage between these two binding
regions. Further supporting our hypothesis is the observation that K90 is contained in two
peptides that mimic regions of FXa sequence that interfere with or block FXa binding to
FVa (10, 40). The fact that K90 is far from the FVa-binding region supports our hypothesis
that these two sites are linked and that binding of synthetic peptides to the FXa dimer
interface interferes with FXa binding to FVa.
4] Linkage between the dimer interface and FVa binding regions of FXa may have
physiological significance in blood coagulation.
Both FXa dimer formation and assembly of the prothrombinase complex are triggered by
C6PS or by binding of these proteins to PS-containing membranes (13, 30, 41, 45). Thus,
the competition between FXa dimer formation and prothrombinase assembly could well
occur on a membrane in vivo. If so, its sensitivity to Ca2+ concentration could be significant
during the early stages of platelet plug formation when calcium concentration in the local
wounded area drops much below normal plasma concentration and increases back to normal
levels within three hours after the injury (46). Thus, we speculate that FXa dimerization is a
mechanism that limits prothrombinase formation when blood clotting is undesirable. We are
investigating this possibility using model membranes.
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Figure 1. Initial Rate of Prothrombin Activation by FXa-FVa at increasing Concentrations of
FVa under Conditions Favoring Dimers
The FXa-FVa interaction was monitored as an increase in the ability of FXa at 5 (squares),
20 (triangles) and 50 (circles) nM concentrations to activate 1 µM prothrombin while
titrating with FVa in the presence of 400 µM C6PS at 5 mM Ca2+. These conditions favor
formation of both the FXa dimer and the FXa-FVa complex.
A) the deviation of experimental data from a value predicted by Model 1 (open symbols)
and Model 5a (closed symbols) relative to the average standard deviation (Rexp – Rfit)/
σmean.
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B) The black curves drawn through the symbols indicate the global fit of the data to a simple
competition model as described in the Supplement (dashed black line) or to the (XaVa)2
model (Model 5a in Supplement; solid black line. Both models assume that the FXa dimer
and XaVa dimer are inactive. Solid red lines represent a fit with hyperbola. Inset: The
apparent Kds of FXa-FVa dissociation were 2.2 ±0.6, 20±4.2, and 43 ± 13.3 nM for 5, 20
and 50 nM FXa, respectively. The inset shows a plot of apparent Kd versus % of monomer
of FXa obtained using Equation 2 in Methods.
Majumder et al. Page 15










Figure 2. Initial Rate of Prothrombin Activation by FXa-FVa at increasing concentrations of
FVa under Conditions Favoring Monomers
Conditions and symbols are as in Figure 1 except that Ca2+ concentration was 3 mM.
A) the deviation of experimental data from a value predicted by the Model 1 (open symbols)
and Model 5a (closed symbols) relative to the average standard deviation (Rexp–Rfit)/σmean.
B) The black curves drawn through the symbols indicate the global fit of the data to a simple
dimer competition model as described in Appendix A (dashed black line) or to an aggregate
model as described in Appendix B (solid black line), both models predict that a dimer or
aggregates are inactive. Solid red lines represent a fit with hyperbola.
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B inset) The apparent equilibrium constants (Kd) for FXa-FVa dissociation were 1.7 ± 0.4,
5.8 ± 0.8, and 8.6 ± 1.2 nM for 5, 20 and 50 nM FXa, respectively. The inset shows a plot of
apparent Kd versus % of monomer obtained using Equation 2 in Methods.
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3A. Native Gel Electrophoresis of a FXa and FVa Mixture in the Presence and Absence
of C6PS. A 5% polyacrylamide gel of a mixture 50 nM FXa and 50 nM FVa in the presence
of 400 µM C6PS and 5 mM Ca2+ (lane 1) shows coexistence of homodimers (FXa ·FXa; 90
KD), heterodimers (FXa · FVa; 224 KD), and FVa (178 KD), showing that FXa monomer
interacts with both FVa and with FXa, thus consistent with the hypothesis that FXa and FVa
compete to bind FXa. Lane 2 shows that the same reaction mixture in the absence of C6PS
contains only monomers of both FVa and FXa, showing that this competition is regulated by
phosphatidylserine (in this case C6PS). Lane 3 shows molecular mass markers.
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3B: Native Gel Electrophoresis of FXa and its GLA-EGFNC Fragment. 8% native
polyacrylamide gel electrophoresis of FXa and GLA-EGFNC fragment of FXa in the
presence and absence of µM 400 C6PS and 5 mM Ca2+ shows that the GLA-EGFNC
fragment does not dimerize in the presence of C6PS and 5 mM Ca2+. Figure 3C: 5% native
polyacrylamide gel electrophoresis of 50 nM FVa with and without 50 nM GLA-αEGFNC
domain in the presence of 400 µM C6PS, 5 mM Ca2+. The results show that the GLA-
EGFNC fragment of FXa does not form a complex with FVa.
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Figure 4. Prothrombin activation by increasing concentration of wild type and mutant (R165A)
FXa in the presence of C6PS and 5 mM Ca2+
The initial rates of prothrombin activation by FXa in the presence of FVa and 400 µM C6PS
at different of FXa concentrations were plotted as a function of FXa. The appearance of
thrombin was determined by the rate of hydrolysis of DAPA (as described in Methods) at
37°C. The reaction was carried out at increasing concentrations of wild type FXa (closed
circles) and mutant R165A FXa (open circles). The reaction mixture contained 1 µM
prothrombin, FXa in 50 mM Tris, 175 nM NaCl, 0.6% poly(ethylene glycol), 5 mM Ca+2
and 400 µM C6PS. The dimerization Kds obtained in the presence of wild type and mutant
FXa are 16 and 147 nM respectively.
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Table 1
Goodness of fit reduced chi-squared  and best fit parameters obtained by simultaneously fitting all three
data sets (5, 20, and 50 nM Xa tot) by either the simple Xa dimer – prothrombinase competition model (Model
1, Supplement) or the (XaVa)2 plus Xa dimer model (Model 5a, Supplement).







1) simple Xa2 XaVa comp./0.1 1.38 0.32 +0.73 −0.31 / 9.8 ± 0.9
5a) (XaVa)2 aggregate from XaVa/0.29
  2XaVa↔(XaVa)2
1.14 0.43 ± 0.3 150 +80 −50 11 ± 0.6







1) simple Xa2 XaVa comp. /0.09 1.41 0.76 +2 −0.74 / 7.2 ± 0.8
5a) (XaVa)2 aggregate from XaVa/0.17
  2XaVa↔(XaVa)2
1.25 1.5 +2 −1.1 166 +230 −80 8.7 ± 0.9
Fixed parameters at 5 mM Ca for both models: Kd Xa2 = 14 nM, and kcat/KM Xa = 1.36x 104 M−1s−1 as measured previously (Majumder et al.,
2003).
Fixed parameters at 3 mM Ca for both models: Kd Xa2 = 600 nM, and kcat/KM Xa = 1.36x 104 M−1s−1 as determined in this paper.
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Table 2
Apparent Dissociation Constants for Interactions of Wild-Type and R165A Mutant FXa with FVa
FXa, nM Kd,app FXa-FVa, nM
Wild Type FXa Mutant
(R165A) FXa
5 2.2 ± 0.6 58 ± 7
20 20 ± 4.2 92 ± 12
50 43 ± 13.3 128 ± 27
Kddimer, nM
Wild Type FXa Mutant
(R165A) FXa
16 ± 4 147 ± 25
Dissociation constants obtained from the data plotted in Figure 1B and from similar experiments with R165A rHFXa show that the R165A
mutation in FXa inhibits both the interaction with FVa and FXa dimer formation. The value of  was obtained from fitting the data in the
figure. We previously reported a value of 14 ± 1 nM obtained from more extensive sets of data in the absence of FVa (13).
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